Previous 10 | Next 10 |
- Data from ongoing trial suggest clinical benefit for ENPP1 Deficiency, including improvement in key biomarkers, patient reported outcomes (PROs) and functional outcomes - - Improvement in the Global Impression of Change (GIC) observed in all three dose cohorts in ABCC6 Deficiency (PXE) tr...
BOSTON, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY)(“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferatio...
2023-09-08 17:10:24 ET Gainers: Vigil Neuroscience ( NASDAQ: VIGL ) +7% . Tenaya Therapeutics ( TNYA ) +4% . CorMedix ( CRMD ) +4% . Xeris Biopharma ( XERS ) +3% . Avidity Biosciences ( RNA ) +3% . Losers: The L...
BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company&...
2023-08-29 04:24:41 ET Summary Inozyme Pharma specializes in rare diseases with INZ-701 as its lead product; faced a stock decline after INZ-701 updates. Company boasts strong financials; $140.2M assets (plus $64.5M from an August equity raise), >2 years of runway, positive INZ...
2023-08-08 14:22:05 ET Inozyme Pharma press release ( NASDAQ: INZY ): Q2 GAAP EPS of -$0.35 beats by $0.08 . Cash, cash equivalents, and short-term investments were $140.2 million as of June 30, 2023. Based on its current plans, the Company now anticipates its cash...
2023-08-08 11:23:45 ET What Are Penny Stocks? Penny stocks are shares of companies trading for under $5. They generally are the stock of companies in early or development stages that are typically smaller in size. While the vast majority of penny stocks trade on the OTC market or ...
2023-08-08 10:40:52 ET Inozyme Pharma press release ( NASDAQ: INZY ): Q2 GAAP EPS of -$0.35. Cash Position and Financial Guidance. Cash, cash equivalents, and short-term investments were $140.2 million as of June 30, 2023. For further details see: Inozyme Pharma ...
– Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency expected in September 2023 – – Plasma pyrophosphate (PPi) to serve as primary endpoint in the U.S. and co-primary endpoint in the EU for ENERGY-3 pe...
2023-08-04 10:54:17 ET Penny stocks are an interesting asset class when it comes to making money in the stock market. Their inherent risk/reward makeup lends to heavy speculation and a thirst for significant gains. On any given day, you’ll likely see at least a few of these cheap sto...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 20:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, July 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal prolifer...
BOSTON, June 21, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferatio...